Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC07-523LS and Vorinostat for HIV Latency
NCT03803605Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Feb 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies, Classical Binding Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VRC07-523LS and vorinostat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event at 36 weeks. Started Feb 2019; status: completed.
02
Drugs
VRC07-523LSvorinostat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03803605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803605.